Replies to post #244621 on Biotech Values

[TwoNE1]

$SPRY / $AQST: FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for neffy® (Intranasal (IN) Epinephrine) for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis

https://finance.yahoo.com/news/fda-advisory-committee-votes-support-230100445.html

$AQST
Aquestive will most likely benefit from this decision as it will simplify the eventual approval of their product (sublingual epinephrine film).
https://www.healio.com/news/allergy-asthma/20230315/sublingual-epinephrine-film-beats-syringes-autoinjectors-in-time-to-maximum-concentration